UNSPSC 51393104: Vesnarinone

This classification denotes a phosphodiesterase inhibitor and antineoplastic antibiotic with the molecular formula C22H25N3O4, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 5COW40EV8M, chemically known as 3,4-dihydro-6-(4-(3,4-dimethoxybenzoyl)-1-piperazinyl)-2(1h)-quinolinone but generally known as vesnarinone, which bears US NIH Compound Identifier 5663. European Medicines Agency schedules Vesnarinone in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB00045MIG.

UNSPSC 51393104 Vesnarinone, a Commodity code, spans pharmaceutical products and related health-supply procurement by state and local health agencies, though recent activity under this specific code shows limited direct alignment with the code's nominal drug classification. The Seminole County, Florida IFB for naloxone and drug deactivation systems (IFB60459723LAS, due July 26, 2023) represents the clearest recent state-local solicitation tagged to this code, purchasing 1,900 units of naloxone and 800 safe drug deactivation systems annually through competitive bidding with quarterly deliveries to the county's community health building. State health and human services agencies also appear in the recent opportunity set; the Texas Health and Human Services Commission issued a Request for Information (RFI HHS0017013, posted April 3, 2026) to gather vendor capabilities on direct-to-manufacturer prescription fulfillment models, signaling exploratory procurement activity ahead of formal solicitation. Issuing bodies include county health departments and state HHS commissions conducting pharmaceutical and health-supply acquisitions, though the code shows sparse recent activity overall.

Geographic spread across recent opportunities centers on Florida and Texas, with the Seminole County purchase representing county-level health procurement and the Texas RFI representing state-level HHS pharmacy benefit strategy. The Seminole County IFB required unit pricing, e-procurement portal submission, drug-free workplace certification, E-Verify compliance, and standard insurance coverage; the Texas RFI sought market intelligence on direct manufacturer contracting outside traditional pharmacy benefit manager and group purchasing organization channels without specifying award values or formal evaluation criteria at the information-gathering stage. Neither opportunity names incumbent vendors or explicit disadvantaged-enterprise set-asides.